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creativecommons.org/licenses/by-nc-nd/Abstract Aim: To evaluate long-term durability of blinatumomab, a BiTE (bispecific T-cell
engager) molecule, in adults with relapsed/refractory (R/R) Philadelphia chromosomeepositive
(Phþ) B-cell precursor acute lymphoblastic leukaemia (ALL).
Me t h o d s : I n t h i s fi n a l a n a l y s i s o f a n o p e n - l a b e l , s i n g l e - a rm , p h a s e 2 ,
multicentre ALCANTARA study (NCT02000427), adults (age 18 years) with Phþ ALL
who had relapsed or were refractory to at least one TKI were included. The primary endpoint
was the proportion of patients who achieved complete remission (CR)/CR with partial haema-
tologic recovery (CRh) during the first two cycles of blinatumomab treatment.irst.emr.it (G. Martinelli).
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
G. Martinelli et al. / European Journal of Cancer 146 (2021) 107e114108Results: The final analysis included 45 patients who completed the study between 3rd January
2014 and 6th January 2017, of which 16 (35.6%; 95% CI, 21.9%e51.2%) achieved CR/CRh
within the first two blinatumomab cycles. After a median follow-up of 16.1 months, median
relapse-free survival (RFS) was 6.8 (95% CI, 4.4enot estimable [NE]) months. Median overall
survival (OS) was 9.0 (95% CI, 5.7e13.5) months with a median follow-up of 25.1 months. Me-
dianOS in patients with CR (19.8 [95%CI, 12.1eNE]months) was greater than in those without
CR (6.0 [95%CI, 2.9e7.1] months). Of 16 patients with CR/CRh, 14 achieved complete minimal
residual disease (MRD) response; themedian duration of completeMRD response was 9.7 (95%
CI, 5.2eNE) months. Treatment-related adverse events were consistent with those previously
reported.
Conclusion: Long-term durability of responses to blinatumomab was demonstrated in patients
with R/R Phþ ALL.
ª 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The Philadelphia (Ph) chromosome, characterised by
t(9;22)(q34;q11) translocation, is the most common
cytogenetic abnormality found in patients with acute
lymphoblastic leukaemia (ALL) [1,2]. Approximately
25% of adults with B-cell precursor (BCP) ALL
constitutes Ph chromosomeepositive (Phþ) ALL
characterised by a BCR-ABL1 fusion gene formed on
the Ph chromosome [1,3]. This gene encodes a
tyrosine kinase with dysregulated activity and is
responsible for leukaemia [4]. BCR-ABL1 protein-
specific tyrosine kinase inhibitors (TKIs) play a key
role in the treatment of Phþ ALL [5]. Although
complete remission (CR) rates > 90% were reported
when TKIs were either included in conventional in-
duction therapy or used alone, relapse occurred in
14%e48% of patients and was associated with
resistance substitutions in the ABL kinase domain
[6e11]. Hence, alternative therapies are needed for
the treatment of patients with relapsed/refractory (R/
R) Phþ ALL.
Blinatumomab, a BiTE (bispecific T-cell engager)
molecule, is engineered to engage cytotoxic T cells
with CD19 expressing B cells, thereby leading to the
lysis of the targeted B cells [12]. Blinatumomab is
indicated for the treatment of adults and children
with R/R BCP ALL and BCP ALL with minimal
residual disease (MRD) [13]. Results from the pri-
mary analysis of a phase 2 study in patients with
Phþ BCP ALL who had relapsed or were refractory
to TKIs reported that blinatumomab was efficacious
with adverse events (AEs) consistent with previous
experience in patients with Phe BCP ALL [3]. A
propensity score analysis of these data compared
with historical control data of patients who received
standard of care (i.e., induction chemotherapy plus
TKI) after the failure of or resistance to treatment
with second-generation TKIs further supports blina-
tumomab as a treatment option in patients with R/RPhþ ALL [14]. As an extension of the primary
analysis [3], we report findings from the final analysis
after a long-term follow-up period.2. Methods
2.1. Patients
As previously described [3], this was an open-label,
single-arm, phase 2, multicentre study to evaluate
the efficacy and safety of blinatumomab in patients
with R/R Phþ ALL conducted across 19 centres in
France, Germany, Italy, the United Kingdom and the
United States (NCT02000427). In this final analysis,
safety and efficacy analyses were re-run and updated
from the primary analysis. Adults (age  18 years)
with Phþ ALL BCP ALL who had relapsed after or
were refractory to at least one second-generation or
later TKI (dasatinib, nilotinib, bosutinib and ponati-
nib), or were intolerant to second-generation or later
TKIs and intolerant or refractory to imatinib mesylate
were included in the study. Key exclusion criteria were
history or presence of clinically relevant central ner-
vous system (CNS) pathology, active CNS ALL,
active acute or chronic (grades 2e4) graft-versus-host
disease, systemic treatment of graft-versus-host disease
within 2 weeks before treatment start, allogeneic
haematopoietic stem cell transplantation (alloHSCT)
within 12 weeks before the start of blinatumomab
treatment, and isolated extramedullary disease. Any
TKI therapy, anti-tumour therapy other than blina-
tumomab, chronic systemic high-dose corticosteroid
therapy, or other immunosuppressive therapies were
prohibited during treatment. Appropriate protocol
approvals were obtained from the ethics committee at
each study site. The studies were conducted in
conformance with Good Clinical Practice standards.
All patients provided written informed consent before
the start of the study.
Fig. 1. Patient disposition. AE, adverse event.
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The study included a 3-week screening and pre-phase
period, an induction treatment period, a consolidation
treatment period, and a safety follow-up visit 30 days
after treatment. Each treatment cycle consisted of 4
weeks of continuous intravenous (cIV) infusion of
blinatumomab followed by a 2-week treatment-free
interval. In the first cycle, blinatumomab was admin-
istered as a cIV infusion in adult patients at 9 mg/day
in week 1 followed by 28 mg/day during weeks 2e4. In
subsequent cycles, patients received blinatumomab at
28 mg/day during weeks 1e4. Patients received two
cycles initially for induction of remission. CR was
defined as  5% bone marrow blasts, platelets
> 100,000/mL, and absolute neutrophil count
(ANC) > 1000/mL. CR with partial haematologic re-
covery (CRh) was defined as  5% bone marrow
blasts, platelets > 50,000/mL, and ANC > 500/mL.
Three additional consolidation cycles were adminis-
tered to patients who had achieved CR/CRh during
the induction treatment period. A total of six long-
term follow-up visits (every 3 months for 18 months)
were scheduled after the safety follow-up visit to
evaluate overall survival (OS) and response duration.
Additional details of the treatment cycles, including
those of blinatumomab and dexamethasone adminis-
tration, have been reported previously [3]. MRD
response was determined by BCR-ABL1 quantification
only for patients achieving CR/CRh. Complete MRD
response was defined as no detectable BCR-ABL1
transcripts by allele-specific real-time quantitative
polymerase chain reaction (RT-PCR) with an internal
ABL amplification control as established by a central
laboratory (LabCorp, Burlington, NC, USA; assay
sensitivity  105; 0.00% BCR-ABL1/ABL1).
2.3. Endpoints and statistical analysis
Safety and efficacy analyses were performed on a full
analysis set that included all patients who received at
least one dose of blinatumomab infusion. In cycles
1e5, 45 (100%), 28 (62%), 12 (27%), nine (20%) and
seven (16%) patients started blinatumomab treatment
cycles, respectively. The primary endpoint was to
evaluate the proportion of patients who achieved
CR/CRh during the first two cycles of blinatumomab
treatment, wherein an exact binomial 95% confidence
interval (CI) was provided. The sample size was
calculated for Simon’s two-stage design based on a
one-sided type I error of 0.025 and a power of 90%
to detect the effective response rate assumption of
 30% over an ineffective treatment rate of  10%.The secondary endpoints included MRD responses
during the first two cycles of treatment, relapse-free
survival (RFS), duration of CR/CRh, OS, alloHSCT
after blinatumomab-induced remission and 100-day
mortality rate after alloHSCT. Endpoints have been
defined previously [3]. The Kaplan-Meier method was
used to estimate the duration of CR/CRh, RFS, OS and
100-day mortality rate following alloHSCT.3. Results
3.1. Patient disposition, demographics and baseline
characteristics
The final analysis involved all patients who completed
the study between 3rd January 2014 and 6th January
2017. Of the 61 patients screened, 45 patients (74%) were
enrolled in the study. A majority of the patients dis-
continued treatment due to protocol-specified criteria
(56%), including premature end of the induction phase
due to disease, or clinical progression without prior CR/
CRh/CR with incomplete haematologic recovery (27%),
intention to receive alloHSCT (13%), failure to achieve
response within two blinatumomab cycles (9%) and
occurrence of haematologic or extramedullary relapse
subsequent to achieving response on treatment (7%); six
patients completed the consolidation treatment period
(13%; Fig. 1). A total of eight patients (18%) completed
the study, and 37 patients (82%) had died by the end of
the study.
Demographics and baseline characteristics of patients
who were enrolled in the study were reported previously
[3]. The median age of patients was 55 years (range,
23e78 years). A majority of patients had received  2
prior TKIs, including 39 (87%) patients treated with
dasatinib. A total of 34 (76%) patients had  50% bone
G. Martinelli et al. / European Journal of Cancer 146 (2021) 107e114110marrow blasts, and 20 (44%) patients underwent prior
alloHSCT.
3.2. Response
3.2.1. Best overall response of CR/CRh within the first
two cycles
The data pertaining to the primary efficacy endpoint
were similar to the outcomes of primary analysis in the
full analysis set (N Z 45) [3]. In the primary analysis, 16
(35.6%; 95% CI, 21.9%e51.2%) patients achieved CR/
CRh within the first two cycles of blinatumomab treat-
ment; the result remained unchanged at the time of the
final analysis. Of these, 14 (31.1%; 95% CI, 18.2%e
46.6%) patients achieved CR and two (4.4%; 95% CI,
0.5%e15.1%) achieved CRh.
3.2.2. MRD response during the first two cycles
The MRD response data were similar in the primary
and final analysis for patients in the full analysis set. A
complete MRD response was observed in 14 of the 16
(87.5%; 95% CI, 61.7%e98.4%) CR/CRh responders, of
which 12 (85.7%) patients had a CR and two (100%)
patients had a CRh.
3.3. Survival
3.3.1. RFS
The median RFS was 6.8 (95% CI, 4.4enot estimable
[NE]) months, with a median follow-up of 16.1 (95% CI,
10.6e22.6) months in patients with a CR/CRh. Of the
16 responders after two blinatumomab cycles, five (31%)
patients were relapse-free, ten (63%) had a relapse and
one patient died. A sensitivity analysis that censored
prior to transplant showed similar results (Fig. 2). Me-
dian RFS in patients with CR/CRh in the first twoFig. 2. Relapse-free survival. Vertical bars indicate censoring. alloHS
fidence interval; NE, not estimable; RFS, relapse-free survival.blinatumomab cycles with P190 isoform of BCR-ABL1
(nZ 10) was 6.7 (95% CI, 3.7eNE) months and was NE
with P210 isoform.
3.3.2. OS
The median OS was 9.0 (95% CI, 5.7e13.5) months with
a median follow-up of 25.1 (95% CI, 20.8e25.9) months.
Of the 45 patients included in the analysis, eight (18%)
were alive. The median OS was not impacted when
censoring for alloHSCT (9.0 [95% CI, 5.7e13.5]
months) with a similar median follow-up duration (24.8
[95% CI, 10.9e25.9] months). Additionally, the median
OS in patients with CR/CRh (23.0 [95% CI, 12.6eNE]
months) was greater than that in patients without CR/
CRh (5.7 [95% CI, 3.4e6.5] months); median OS for the
14 patients with complete MRD response was not esti-
mable (Fig. 3).
In a subgroup of patients with BCR-ABL1 mutations
(n Z 17), the median OS was 6.5 (95% CI, 4.2eNE)
months. Median OS was not estimable for 10 patients
with T315I mutations and was 5.6 (95% CI, 0.8e12.1)
months in seven patients with mutations other than
T315I. In a subgroup of patients with P190 (nZ 26) and
P210 isoforms (n Z 16) of BCR-ABL1, the median OS
was 12.1 (95% CI, 5.3eNE) months and 6.4 (95% CI,
2.9eNE) months, respectively.
3.3.3. Duration of remission
The median time to haematologic relapse (duration of
remission) for the 16 CR/CRh responders was 6.8 (95%
CI, 4.5eNE) months. Eleven of 16 CR/CRh responders
received TKIs during the long-term follow-up period.
Censoring prior to the time of alloHSCT did not alter
the duration of remission (6.7 [95% CI, 3.8eNE]
months). The duration of remission was 9.7 (95% CI,
5.2eNE) months for the complete MRD respondersCT, allogeneic haematopoietic stem cell transplantation; CI, con-
Fig. 3. Overall survival. Vertical bars indicate censoring. CI, confidence interval; CR, complete remission; CRh, CR with partial hae-
matologic recovery; MRD, minimal residual disease; NE, not estimable; OS, overall survival.
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disease at the end of the follow-up period. Of these five
patients, four achieved durable responses without
alloHSCT. Three of the four long-term survivors
without alloHSCT received TKI therapy during the
follow-up period; one remained MRD negative with
neither alloHSCT nor additional TKI therapy.
3.4. AlloHSCT and 100-day mortality rate after
alloHSCT
A total of nine patients (20%) received alloHSCT. Of
these nine, four (8.9%) were in remission after CR/CRh
within the first two cycles and received no anti-Fig. 4. Duration of remission in complete MRD responders. Vertica
remission; CRh, CR with partial haematologic recovery; MRD, minimleukaemic medication after blinatumomab therapy
(Table 1). The 100-day mortality rate in these four pa-
tients who received an alloHSCT while in
blinatumomab-induced remission was 25% (one death).
Additionally, the median survival after alloHSCT in
these four patients was 15.9 (95% CI, 2.1e16.9) months.
3.5. Safety
The incidence of treatment-emergent AEs (TEAEs) and
treatment-related AEs is summarised in Table 2. The
most frequent treatment-related grade  3 AEs included
febrile neutropenia (11%) and elevated levels of alanine
aminotransferase (11%); the most frequent treatment-l bars indicate censoring. CI, confidence interval; CR, complete
al residual disease; NE, not estimable.
Table 1
Disease status at the time of alloHSCT.
Blinatumomab
(N Z 45)
Disease status at the time of alloHSCT, n (%) 9 (20.0)
In remission after CR/CRh within the first
two cycles and no anti-leukaemic
medication after blinatumomab therapya
4 (8.9)
In remission after CR/CRh within the first
two cycles and with anti-leukaemic
medication after blinatumomab therapya
1 (2.2)
Not in remission after CR/CRh within
the first two cycles
2 (4.4)
Not having reached CR/CRh within
the first two cycles
2 (4.4)
alloHSCT, allogeneic haematopoietic stem cell transplantation; CR,
complete remission; CRh, CR with partial haematologic recovery.
a Excluding conditioning regimens.
G. Martinelli et al. / European Journal of Cancer 146 (2021) 107e114112related serious AEs included tremor (7%) and febrile
neutropenia (4%). Cytokine release syndrome occurred
in four patients (9%), but none were grade  3 and led
to treatment interruption or discontinuation. Neuro-
logic events occurred in 28 (62%) patients, of which six
(13%) were grade  3 and four (9%) led to treatment
interruption.
Five patients (11%) had fatal AEs: multiple organ
dysfunction syndrome, sepsis, septic shock, cerebral
haemorrhage, and respiratory failure; one death due to
septic shock was considered to be treatment-related by
the investigator.
4. Discussion
In this final analysis of long-term outcomes following
single-agent blinatumomab in heavily pretreated adults
with R/R Phþ ALL, responses to blinatumomab were
durable with five of 16 (31%) CR/CRh responders
remaining relapse-free, and no impact on median RFS
or OS was detected when censoring for alloHSCT. In
general, the efficacy and safety findings from the final
analysis were consistent with that reported for the pri-
mary analysis; no new safety signals were observed [3].Table 2
Incidence of AEs.





All AEs 45 (100) 41 (91)
Grade  3 38 (84) 20 (44)
Grade  4 18 (40) 7 (16)
Serious AEs 28 (62) 12 (27)
Leading to discontinuation of
blinatumomab
3 (7) 2 (4)
Serious 2 (4) 1 (2)
Leading to interruption of
blinatumomab
17 (38) 12 (27)
Serious 13 (29) 7 (16)
Fatal AEs 5 (11) 1 (2)
AE, adverse event; TEAE, treatment-emergent AE.Due to their efficacy against a malfunctioning tyro-
sine kinase encoded by BCR-ABL1 fusion gene, BCR-
ABL1 protein-specific TKIs play a key role in the
treatment of Phþ ALL. Inclusion of TKI in frontline
treatment regimens has improved long-term survival in
patients with newly diagnosed Phþ BCP ALL [7,15,16].
Results from an open-label, multicentre, phase 2 trial
(PACE) in patients with chronic myeloid leukaemia
(CML) or Phþ ALL treated with ponatinib, a third-
generation TKI, demonstrated that 41% (95% CI,
24%e59%) of patients had a major haematologic
response with a median duration of 3 (range, 2 to > 14)
months, 47% had a major cytogenic response and 38%
had a complete cytogenic response [17]. However, mu-
tations in ABL kinase domain are associated with
resistance to TKI therapy [18]. The targeted lysis of B
cells by blinatumomab, which is achieved by engaging
CD3þ cytotoxic T cells with CD19 expressing B cells, is
independent of the presence of mutations in the ABL
kinase domain. With its distinct mode of action, blina-
tumomab can thus overcome the resistance associated
with TKI therapy, and the inclusion of blinatumomab in
combination treatment regimens with TKIs could
further improve treatment outcomes. In this regard, a
retrospective study reported the efficacy and safety of a
combination of blinatumomab with TKIs such as
bosutinib, dasatinib, or ponatinib (n Z 12) in patients
with R/R heavily pretreated Phþ ALL or CML in
lymphoid blast crisis [19]. In another retrospective study
(n Z 13), eight of nine patients evaluable for response
achieved complete molecular response (CMR) after a
median of one cycle (range, one cycle to two cycles) of
treatment with a combination of blinatumomab and
TKIs. The median duration of follow-up among survi-
vors was 10.8 (range, 3.5 to 20.0) months; three patients
underwent alloHSCT in CMR [20]. Results from
another retrospective study conducted across eight
French centres (n Z 15) indicated that 14 of 15 (93%)
patients with R/R Phþ ALL, who received a combina-
tion of blinatumomab and ponatinib, achieved a cyto-
logic CR [21]. Additional trials evaluating the efficacy
and safety of the combination of blinatumomab and
TKIs with or without chemotherapy are ongoing
[22e24].
Although the outcomes are encouraging, the small
sample size of patients involved in this study limits our
ability to draw firm conclusions. Another limitation of
the study was the use of RT-PCR for the determination
of MRD response. Although quantitative detection of
clonal immunoglobulin and T-cell receptor gene rear-
rangements or flow cytometry analysis might have been
better methods to analyse MRD status, RT-PCR was a
more commonly used technique when this study was
planned and conducted. In summary, the final analysis
of the efficacy and safety data demonstrates the long-
term durability of responses to single-agent blinatumo-
mab in patients with R/R Phþ ALL.
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